Login to Your Account



Basilea Hits Historic High On Phase III Ceftobiprole Data

By Cormac Sheridan


Wednesday, January 17, 2007
Shares in Basilea Pharmaceutica AG hit an all-time high on the Swiss Stock Exchange in Zurich last Friday of CHF240 (US$192), on good news about its broad-spectrum cephalosporin antibiotic ceftobiprole. Research analysis showed that ceftobiprole attained the primary endpoint of statistical non-inferiority versus a comparator combination therapy in a Phase III pivotal trial in patients with complicated skin and skin structure infection (cSSSI). (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription